L-Asparaginase (L-ASNase) is an important biopharmaceutical used for the treatment of acute lymphoblastic leukemia. Since L-ASNase is a biological product isolated from bacteria, extensive purification steps are necessary to obtain a pure preparation, which in turn, negatively impacts the costs related to its manufacturing. More economical and efficient alternatives to obtain this bioproduct are therefore required. In this context, we propose to evaluate the possibility to use cell-free protein synthesis systems in order to obtain a pure Erwinia chrysanthemi recombinant L-ASNase. The technology consists in the use of cellular extracts and energetic substrates capable of expressing recombinant proteins in vitro, thus dispensing the use of living cells in the process. The technology has demonstrated high protein expression efficiency, it is scalable to different reaction volumes and the open environment allows for greater process control and immediate evaluation of protein expression levels achieved. The expression of L-ASNase in this technology would simplify its biotechnological process and facilitate the study and characterization of novel forms of the enzyme, in addition to contributing to the improvement and advancement of cell-free protein synthesis technology within the biopharmaceutical industry.
News published in Agência FAPESP Newsletter about the scholarship: